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Summary
Fabry disease is an X-linked lysosomal disorder that results 
from a deficiency of the lysosomal enzyme a-galactosidase A 
leading to accumulation of glycolipids, mainly globotriaosylcera- 
mide in the cells from different tissues. Classical Fabry disease 
affects various organs. Clinical manifestations start at early age 
and include angiokeratoma, acroparesthesia, hypohydrosis, 
heat/exercise intolerance, gastrointestinal pain, diarrhea, and 
fever. The main complications of Fabry disease are more prom­
inent after the age of 30 when kidney, heart, and/or cerebrovas­
cular disorders appear. Most of the heterozygous females are 
symptomatic. Enzyme replacement therapy (ERT) is the only 
specific treatment for Fabry disease. The beneficial effect of 
ERT on different organs/systems has been extensively eval­
uated. Quality of life of patients receiving ERT is improved. 
Enzyme replacement stabilizes or slows the decline in renal 
function and reduces left ventricular hypertrophy. Fabry dis­
ease may be underdiagnosed because of nonspecific and multi­
organ symptoms. Different screening strategies have been car­
ried out in different at-risk populations in order to detect 
undiagnosed Fabry patients. An increasing knowledge about 
Fabry disease within the medical community increases the 
chances of patients to receive a timely diagnosis and, conse­
quently, to access the appropriate therapy. © 2009 IUBMB
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INTRODUCTION
Fabry disease (OMIM 301500) is an X-linked disorder of 
glycosphingolipid catabolism that results from a deficiency of 
the lysosomal enzyme a-galactosidase A (a-D-galactoside galac­
tohydrolase, EC 3.2.1.22; a-Gal A) (7, 2). Patients with absolute
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deficiency of a-Gal A activity present the classical Fabry pheno­
type, whereas those with residual activity have a milder or 
later-onset variant. This defect leads to the accumulation of the 
enzyme substrates, mainly globotriaosylceramide (Gal a I—4Gal 
/i I—4Glc /i 1-lCer; Gb3; or ceramide trihexoside) in lysosomes 
of a variety of different cell types throughout the body (3). It 
was initially described as “angiokeratoma corporis diffusum” 
by the dermatologists Johannes Fabry (4) and William Ander­
son (5) in 1898.
INCIDENCE
The incidence of Fabry disease has been estimated to range 
from 1/40,000 to 1/117,000 live births for males (6, 7). No eth­
nic predilection has been observed. Fabry disease may be 
underdiagnosed because of nonspecific and multiorgan symp­
toms. Moreover, it is supposed that many heterozygotes remain 
undiagnosed, due to the less severe clinical manifestations of 
female patients.
A recent report on a screening test for newborns in Italy has 
found an incidence of a-Gal A deficiency of 1/3,100 newborn 
males (8). However, all but one of the newborns identified in 
this study had mutations predicting the later-onset phenotype. 
Taking into account the unique case with the classical pheno­
type associated-mutation, the incidence of this phenotype would 
be 1/37,000, consistent with reported estimates (7). Therefore, 
the estimated ratio of later-onset:classical phenotypes would be 
11:1.
CLINICAL MANIFESTATIONS
Lysosomal storage diseases (LSD) usually present a wide 
spectrum of clinical severity. Fabry disease is not an exception. 
The most severe presentation accounts for the classical disease, 
which affects various organs. Patients with the classical form 
have low or very little GLA activity. Milder or later-onset var­
iants with manifestations circumscribed mainly to one organ, 
such as, the “cardiac variant” and “the renal variant," have 
been also described (9, 10). Patients with this mild presentation 
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have residual a-galactosidase A activity (between 1 and 20% of 
normal levels).
Cardiac Variant
Clinical manifestations are limited to heart and present in the 
sixth or seventh decade of life. This variant is characterized by 
left ventricular concentric hypertrophy, and by the lack of 
angiokeratoma, acroparesthesias, hypohydrosis, or corneal opac­
ities. Proteinuria can be present but renal function is generally 
not affected. Mutations detected in cardiac variant patients' are 
missense mutations or intronic lesions that reduced mRNA lev­
els (70).
Renal Variant
Patients develop end-stage renal disease at ages similar to 
those of classically affected patients, but lack the other classical 
manifestations. Most of these cases are initially diagnosed as 
chronic glomerulonephritis (9).
Classical Fabry Disease
Patients with classical Fabry disease show signs and symp­
toms affecting various organs. In affected patients with classical 
Fabry disease, manifestations start at early age, during the first 
decade of life. Symptoms, such as, acroparesthesia, hypohydro­
sis, heat/exercise intolerance, gastrointestinal pain, diarrhea, and 
fever (11-13).
The typical skin manifestation of Fabry disease, the angioker­
atomas present in adolescence and are mainly found in bathing 
trunk area and umbilicus (14). They can be found also in oral 
mucosa, fingers, and thorax. Corneal opacity (cornea verticillata) 
is a frequent sign in Fabry disease, but does not reduce vision, 
and is generally detected by trained ophthalmologists (75).
Male Fabry patients show facial minor dysmorphic features, 
such as, periorbital fullness, prominent supraorbital ridges, 
bushy eyebrows, pronounced nasal angle, generous nose/bulbous 
nasal tip, shallow midface, full lips, prominent nasal bridge, 
broad alar base, and posteriorly rotated ears (76, 77).
Auditory and vestibular symptoms includes tinnitus, hearing 
loss, and vertigo (18). Patients also suffer from cefalea. Psychi­
atric studies revealed a high incidence of severe depression (79) 
that is related to the degree to which symptoms interfered with 
normal life.
The main complications of Fabry disease are more prominent 
after the age of 30 when kidney, heart and/or cerebrovascular 
disorders appear (20). These manifestations are the most fre­
quent cause of death and reduce life expectancy by 20 years 
compared with the normal population. The earliest manifesta­
tion of renal involvement is microalbuminuria or proteinuria. 
During the third decade of life, a progressive reduction of glo­
merular filtration rate develops (27). The decline in renal func­
tion ultimately leads to requirement of dialysis or kidney trans­
plantation. Cardiac complications are diverse, and includes con­
centric hypertrophic miocardiopathy, diastolic dysfunction, and 
valvular or conduction defects (22). Magnetic resonance imag­
ing frequently reveals white matter lesions (23), and cerebrovas­
cular events, such as, transient ischemic attack or stroke occur, 
sometimes before the development of renal or cardiac events 
(24).
Heterozygotes
Fabry disease is an X-linked disorder, neither recessive nor 
dominant (25). The penetrance of Fabry disease in females is quite 
high, with at least 70% of females showing clinical manifestations 
of the disease (26). For this reason, when referring to females with 
Fabry disease, the term “carrier” should be avoided and replaced 
by the term “heterozygotes.” According to the X-linked inheri­
tance of Fabry disease, the number of female cases is likely to 
double that of male cases. However, registries of Fabry disease 
usually contain a similar number of female and male patients en­
rolled. This suggests the existence of a substantial number of 
undiagnosed heterozygous, whose data are missing. For this rea­
son, data from females enrolled in registries should not be inter­
preted as representing the whole universe of heterozygous.
Disease expression in females depends on the chromosome 
X inactivation pattern. As a result of the process of chromo­
some X inactivation (27), females show a mosaic of cells 
expressing genes from maternal origin or paternal origin. Cells 
with normal a-Gal A activity cannot correct the deficiency of 
the enzyme in cells expressing mutant a-Gal A, and both type 
of cells contribute to the organism (26). The ratio between nor­
mal cells and mutant cells determines the phenotype of the 
female patient. Even females with random X inactivation pat­
terns (28) are symptomatic. Unfavorably skewed X inactivation 
may result in a high severity of disease manifestations (29, 30). 
Age at onset of symptoms in females is generally older and 
more variable than in males. Disease manifestations in heterozy­
gotes are more diverse than in males. Severe complications in 
females are most often associated to heart disease and stroke 
(31). Life expectancy of heterozygotes is 70 years, 15 years 
shorter than that of the general female population (20).
TREATMENT
Symptomatic treatment was the only possible therapy for 
Fabry disease until 2001, when a specific treatment by enzyme 
replacement therapy (ERT) became available (32, 33). This 
treatment is based on a biweekly intravenous infusion of the 
recombinant human a-galactosidase A. Two drugs are now 
commercially available: agalsidase alpha (Replagal, Shire HGT) 
and agalsidase beta (Fabrazyme, Genzyme) which are based on 
enzyme preparations produced in human fibroblasts and CHO 
cell line, respectively. Primary structure of both polypeptides is 
the same, but the glycosylation pattern may vary according to 
the species from which the cell line is derived. Studies of both 
proteins suggest that they are biochemically, structurally, and 
functionally equivalent (34). A study comparing both enzymes 
at the same dose did not reveal any difference in clinical effect 
(35).
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The beneficial effect of ERT on different organs/systems has 
been extensively evaluated. Quality of life of patients receiving 
ERT is improved and pain severity is reduced (36). Gastrointes­
tinal manifestations including abdominal pain are alleviated by 
ERT (37). Enzyme replacement stabilizes or slows the decline 
in renal function (38, 39) as opposed to a decline of glomerular 
filtration rate of 7 mL/min/year in nontreated patients (27). 
However, proteinuria does not seem to be improved (40). Stud­
ies in kidney transplanted patients show that ERT is safe and 
effective to reduce the progression of extra-renal manifestations 
of Fabry disease (41, 42). A benefit on cardiac disease has been 
also reported, with a reduction in left ventricular mass in 
patients with left ventricular hypertrophy (43). Agalsidase alpha 
has been shown to stabilize, and possibly improve vestibular 
function (44) and hearing in Fabry patients who have not al­
ready progressed to severe hearing loss (45). However, patients 
suffering from cerebrovascular disease have not shown a signifi­
cant improvement after treatment (46).
In general, therapies based on the infusion of recombinant 
proteins induce a specific immune response due to the immuno­
genicity of the infused polypeptide. Regarding safety and toler­
ability, infusion reactions occur in 10-50% of patients receiving 
agalsidase alfa or beta, respectively. These reactions usually con­
sist of fever, redness, rhinitis, and/or rigors. IgG antibodies de­
velop in 55-80% of patients (32, 33). IgE has been reported in 
patients receiving agalsidase beta (47), but not with agalsidase 
alfa. Treatment related adverse events can be avoided by reduc­
ing the infusion rate and/or by premedication with antihistamines 
and/or corticosteroids. Antibodies against the enzyme seem to 
impair the efficacy of ERT in some patients (48), but more long­
term studies should be carried out to confirm these findings.
Home treatment is feasible and safe, and constitutes clear 
benefit for patients because it produces less alteration of their 
usual activities and improves compliance with this life-long 
ERT (49). Patients receive ERT at hospital under careful medi­
cal supervision for a period of 3-6 months to check for any 
adverse events or complications, and then they can be trans­
ferred to a home infusion setting (50).
Because the experience with ERT for Fabry disease is lim­
ited to the last 8 years, there are no absolute conclusions about 
how ERT is able to change the natural history of Fabry disease. 
Moreover, there are yet no answers to the question about the 
optimal age to start ERT. Taking into account that studies in 
adult patients suggest that ERT could prevent or slow down the 
progression of tissues alterations, it may be hypothesized that 
initiation of ERT at an early age would reduce the massive Gb3 
deposition that leads to irreversible organ damage (57). How­
ever, studies evaluating this concept have not been reported yet. 
site of Gb3 accumulation. Using immunodetection, Gb3 was 
shown to be distributed in other cellular structures including 
ER, cell membrane, and nucleus (52). The distribution of Gb3 
accumulation was heterogeneous among different organs/tissues, 
with the stronger staining found in heart and kidney, the organs 
that accumulate the greatest amounts of Gb3.
Gb3, also known as CD77, is a differentiation antigen 
expressed on B cells in the germinal centers (53). These cells 
undergo rapid and spontaneous apoptosis when isolated and cul­
tured in vitro (54).
The anomalous accumulation of Gb3 in Fabry disease could 
be associated to different mechanisms leading to disease. The 
exact molecular mechanism that translates the primary insult 
into cell damage remains to be determined. Other concurrent 
pathological mechanisms could be elicited, contributing to the 
phenotypic expression of the disease (55). Dr. Schiffmann's 
group has focused its studies on vascular disorder of Fabry dis­
ease, and has demonstrated the presence of abnormalities in 
blood flow, vessel wall, and blood components (56). In terms of 
alterations of blood components, they have detected an inflam- 
mation-activated state in endothelium and leukocytes in Fabry 
disease (57, 58).
Other studies have focused on possible proinflammatory 
aspects of Fabry disease, since the suggestion of the existence of 
a proinflammatory status in Fabry disease (59). There are reports 
showing the coexistence of Fabry disease and autoimmune dis­
orders (60, 61). Abnormalities in the number of immune cell sub­
sets in Fabry patients have been recently described (62). The 
gene NAIP (Neuronal apoptosis inhibitory protein) associated 
with inflammation was found to be upregulated in Fabry children 
(63). Exposure of endothelial cells to Gb3 resulted in increased 
intracellular production of reactive oxygen species (57).
Another compound related to Gb3, lyso Gb3, was recently 
found to be increased in plasma from Fabry patients. This com­
pound has been shown to induce smooth muscle proliferation, 
which could account for the hypertrophy of the wall of blood 
vessels (64).
The phenotypic spectrum of Fabry disease could be due to 
interactions with other genes that could modify the clinical 
expression. This was demonstrated for certain polymorphisms in 
genes coding for endothelial nitric oxide synthase, interleukin-6, 
and factor V Leiden (65, 66).
More studies to detect pathophysiological mechanisms of 
Fabry disease are encouraged in order to understand how the 
primary defect translates into organ damage and clinical 
manifestations. This knowledge would also be beneficial to 
understand the effect of specific therapy and to improve further 
its efficacy.
PATHOPHYSIOLOGY
Alterations observed in Fabry disease are primarily due to 
the deficiency of a-Gal A, and the consequent accumulation of 
glycolipids in lysosomes. However, lysosomes are not only the
DIAGNOSIS
Diagnosis of Index Cases. Fabry disease is difficult to diag­
nose in clinical practice. Disease manifestations in childhood 
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are diverse and unspecific, involve various organs, and are eas­
ily confused with other pathologies, including rheumatic dis­
eases. A previous misdiagnosis is not uncommon (67). Fabry di­
agnosis has been described as an “odyssey”: Fabry patients visit 
an average of 10 different medical specialists along 10 years 
before achieving confirmatory diagnosis. These facts lead to a 
delay of 10 years between age at symptoms onset and age at di­
agnosis. Suspicion of the disease in index cases often comes 
from nephrologists, dermatologists or geneticists, among others. 
For this reason, dissemination of knowledge about Fabry dis­
ease, its diagnosis and the necessity to treat the patient using a 
multidisciplinary biomedical approach is crucial for improving 
Fabry disease diagnosis (68).
Generally, index cases detected by suspicion based on clini­
cal manifestations are affected males. When a new Fabry male 
is diagnosed a new Fabry family is detected. After the diagnosis 
of an index case, a screening of the relatives allows confirma­
tory diagnosis of other affected members.
Confirmatory Diagnosis. As with other LSD, the diagnosis of 
Fabry disease is generally carried out in a reference specialized 
lab. Implementation of the diagnostic methods requires a com­
plete knowledge and grasp of the pathologies by the professio­
nals involved. This requirement adds another obstacle to the 
ready access to a confirmatory diagnosis.
After disease suspicion by a physician, confirmation of diag­
nosis in hemizygous males is made by demonstrating absent or 
reduced GLA enzymatic activity. Because heterozygous females 
can have low or normal GLA activity values, diagnosis confir­
mation in females is not based on enzymatic activity determina­
tion (69). The determination of GLA enzymatic activity is car­
ried out on blood leukocytes or cultured skin fibroblasts. 
Recently, determination of GLA activity on dried blood filter 
paper was introduced (70). This method has proven to be reli­
able with high sensitivity and specificity to diagnose male Fabry 
patients. Blood samples collected in filter paper can be shipped 
to the reference laboratory by ordinary mail during the ensuing 
month without a significant loss of enzymatic activity. The 
implementation of this method allows testing samples from 
patients that are far away from the reference labs, thus improv­
ing patient access to diagnosis.
Genetic testing to identify the disease-causing mutation is 
also a valuable and complementary assay. The detection of a 
given mutation in the index male case leads to testing the pres­
ence of the same mutation in female relatives who may be het­
erozygotes. Genetic testing is the only reliable method to con­
firm diagnosis in females, because the enzymatic activity assay 
in heterozygotes is inconclusive (71).
Fabry disease-causing mutations are private, meaning that 
almost each family has its own mutation (72). There are no fre­
quent mutations as is found, for example, in Gaucher disease 
(73). More than 400 mutations leading to Fabry disease have 
been described in the literature (Human Gene Mutation Data­
base, http//www.hgmd.org). For this reason, genetic testing is 
carried out by direct sequencing of the gene coding for GLA 
(74). GLA gene is formed by seven exons, and the 1,393 bp 
full-length cDNA codes for a precursor peptide of 429 amino 
acids including the 31 residues' signal peptide (75). Alterations 
in the gene includes large rearrangements, splicing defects, 
insertions/deletions, and point mutations. The most common 
alterations are point mutations, including nonsense and missense 
ones. Mutations occurring at different positions in each of the 
seven exons have been described (76).
Genotype-Phenotype Correlation
Although different types of mutations have been reported in 
Fabry disease, the genotype-phenotype correlation is generally 
poor (3). Moreover, the same mutation may cause different phe­
notypes in patients from the same family and different muta­
tions may cause the same phenotype. After the resolution of the 
3D structure of a-galactosidase A (76), a few reports concerning 
correlations between genotype and phenotype have been pub­
lished (77). It is now recognized that phenotypes of even simple 
Mendelian disorders are influenced by complex genetic and 
environmental factors and that genotypes, rarely, absolutely pre­
dict phenotypes (78).
Screenings
Different screening strategies have been carried out in differ­
ent at-risk populations in order to detect undiagnosed Fabry 
patients. Various studies included hemodialysis patients; with a 
frequency of confirmed diagnosis between 0.2 and 1.2% (79, 
80). Other studies have focused on patients with cryptogenic 
stroke or unexplained left ventricular hypertrophy with frequen­
cies between 3 and 6% (81, 82).
One important benefit from detecting a new Fabry patient 
through a screening strategy is the possibility of detection of 
other patients among relatives of the index case. The develop­
ment of targeted protocols and the constitution of interdisci­
plinary groups for the identification of patients with Fabry 
disease are recommended to obtain a higher yield in the screen­
ing process.
Markers
No surrogate biomarker has yet been shown to reflect the 
global burden of Fabry disease activity, or to reflect the global 
response to ERT (83). The potential use of Gb3 as a marker of 
Fabry disease has been extensively evaluated by assaying its 
concentration in plasma and urinary sediment by different meth­
ods (84, 85). Gb3 from urinary sediment comes from desqua­
mated tubular cells and may reflect renal storage. The pattern of 
urinary sediment glycolipids from Fabry male patients revealed 
increased amounts of Gb3 (86), and the values from heterozy­
gotes are between the ones from normal controls and hemizy­
gotes. Moreover, urinary Gb3 excretion was found to correlate 
with type of mutation, sex, and treatment status (87).
Recently, high concentrations of globotriaosylsphingosine in 
plasma were found in male Fabry patients. Although no correla­
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tion with age or disease severity was found, plasma levels were 
reduced in patients receiving ERT (64).
Prenatal and Newborn Screening
Precise heterozygote diagnosis by genetic testing allows to 
offer genetic counseling to couples at risk of having a Fabry 
disease-affected offspring. A heterozygous woman has a 50% 
probability to have affected boys or girls. After the couple 
receive this information, prenatal diagnosis could be offered to­
gether with orientation on advantages and risks of the proce­
dure.
Prenatal diagnosis of Fabry disease could be performed using 
cultured amniocytes or direct and/or cultured chorionic villi 
(CV) (88). The recommended first diagnostic step for the 
genetic counseling of families with Fabry disease history is the 
fetal sex determination (89). After determining fetal sex, mea­
surement of GEA activity and genetic testing are carried out. 
Direct studies of fresh CV provide the initial and rapid diagno­
sis. This initial diagnosis should be confirmed by studies on cul­
tured CV, which also serves to rule out a possible maternal con­
tamination in fresh CV. All prenatal diagnoses should be con­
firmed by analyzing cells or fetal tissues if gestation is 
interrupted or by analyzing plasma and/or leukocytes from cord 
blood after delivery (90). There is some controversy regarding 
prenatal testing in female fetuses. Heterozygozity can be effi­
ciently confirmed by genetic testing but it is not possible to pre­
dict the clinical presentation.
Preimplantatory diagnosis could be done using blastomers 
(90). All preimplantation diagnoses should be confirmed by sub­
sequent CV sampling or amniocentesis.
A debate still exists in relation to application of newborn 
screening not only for Fabry disease but also for all the LSD. 
Because LSDs have a low prevalence when considered individ­
ually, when they are considered as a group the combined esti­
mated prevalence could be as high as 1/7,700 (6). The availabil­
ity of therapy for Fabry disease opened the discussion in terms 
of newborn screening. Diagnosis of Fabry disease, as discussed 
earlier, could take several years. The chronic and progressive 
nature of the disease leads to an irreversible pathology. Early 
detection will enable early instauration of treatment for patients, 
before significant irreversible organ damage develops. On the 
other hand, some individuals remain asymptomatic until late 
age. At this time, as stated earlier, there is no evidence of a 
benefit from the early introduction of therapy. Clinical trials are 
in progress in order to evaluate this.
Attempts have been made to develop multiplex methods to 
analyze various LSDs in a single assay. One of these is based 
on an immunoassay to quantify the enzyme in terms of protein 
mass, taking into account that not only the enzymatic activity 
but also the number of enzyme molecules are reduced in Fabry 
disease (91). The detection of lysosomal enzyme activities in 
dried blood spots could also be multiplexed by using tandem 
mass spectrometry to detect the enzymatically generated product 
(92).
CONCLUSION
Fabry disease is an underdiagnosed pathology. Because of 
the advent of specific therapy, special attention has been given 
to this disease, and important knowledge has been obtained 
regarding its natural history, pathophysiology, and response to 
therapy. Many efforts are currently being made in order to 
improve diagnosis of this disease in different countries. An 
increasing knowledge about Fabry disease within the medical 
community increases the chances of patients to receive a timely 
diagnosis and, consequently, to access the appropriate therapy. 
In the near future, the increasing experience about Fabry disease 
treatment would shed light on the effect of such therapy on the 
clinical course of the disease. It could also suggest the optimal 
age for treatment onset, and could help to decide about the 
necessity of neonatal screening.
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